Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and immunogenicity of seasonal influenza vaccine with and without co-administration of Ad26.RSV.preF in adults aged 60 and o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Ad26.RSV.preF (Ad26.RSV.preF)
• Seasonal influenza vaccine

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Healthy | Phase 2 | Status: COMPLETED | Results posted: 2021-08-18